BURLINGTON, Vt. -- Triosyn Corp., a developer of products aimed at protecting against microbial threats, has announced that tests conducted by Health Canadas national microbiology laboratory show that Triosyn T-1000 series respirators protect against Severe Acute Respiratory Syndrome (SARS). The third-party tests, which validate Triosyns extensive testing, demonstrate that Triosyns filtration technology eliminates SARS viral particles from the air passing through the facemask.
Health Canada, the Canadian federal bureau of health, conducted independent testing on the efficacy of Triosyns facemask filter to protect against SARS coronavirus, the viral agent responsible for SARS. The test involved blowing air contaminated with the SARS coronavirus through the facemask and analyzing the airstreams that passed through the facemask for the presence of viral particles. Tests were conducted at three different exposure periods: 15, 60 and 120 minutes.
Health Canadas test results show that no coronavirus particles were detected in the airstreams that passed through the Triosyn T-1000 series respirator during any of the three different exposure periods.
Health Canadas tests confirm that the T-1000 is the worlds first personal facemask that can provide protection against the potentially deadly airborne SARS virus, said Pierre Jean Messier, CEO of Triosyn Corp. Police forces in North America are currently using the T-1000 facemask and we are introducing it throughout the world.
SARS is a potentially deadly respiratory virus, which currently has no vaccine. More than 8,400 people in 29 countries have contracted SARS, and more than 900 people have died worldwide since the emergence of SARS in November 2002. The World Health Organization (WHO) states that the virus can be transmitted through the air, via coughing or sneezing, on tiny droplets of bodily fluids.
The Triosyn T-1000 respirator, a disposable personal facemask manufactured with an innovative antimicrobial technology to protect the filtration materials from microbial deterioration, is certified by the National Institute for Occupational Safety and Heath (NIOSH) as an N95 filtering facepiece respirator. It is also CE certified in Europe.
Source: Triosyn Corp.
Unraveling a Candida auris Outbreak: Infection Control Challenges in a Burn ICU
March 19th 2025A Candida auris outbreak in a burn intensive care unit (BICU) in Illinois has highlighted the persistent challenges of infection control in high-risk health care settings. Despite rigorous containment efforts, this multidrug-resistant fungal pathogen continued to spread, underscoring the need for enhanced prevention strategies, environmental monitoring, and genomic surveillance.
Unmasking Long COVID: Dr Noah Greenspan on Recovery, Research Gaps, and the Future of Treatment
March 18th 2025Dr Noah Greenspan discusses the evolving understanding of long COVID, current treatment strategies, diagnostic challenges, and the critical need for research and awareness in post-viral syndromes.
From Shortages to Security: How Reusable Health Care Textiles Can Transform Infection Prevention
March 7th 2025Reusable health care textiles enhance infection prevention, reduce waste, and strengthen supply chains. Hygienically clean textiles offer a sustainable, cost-effective alternative to disposable PPE, ensuring patient safety and environmental responsibility.